Levodopa
- Generic Name
- Levodopa
- Brand Names
- Dhivy, Duodopa, Duopa, Inbrija, Parcopa, Prolopa, Rytary, Sinemet, Stalevo
- Drug Type
- Small Molecule
- Chemical Formula
- C9H11NO4
- CAS Number
- 59-92-7
- Unique Ingredient Identifier
- 46627O600J
- Background
Levodopa is a prodrug of dopamine that is administered to patients with Parkinson's due to its ability to cross the blood-brain barrier. Levodopa can be metabolised to dopamine on either side of the blood-brain barrier and so it is generally administered with a dopa decarboxylase inhibitor like carbidopa to prevent metabolism until after it has crossed the b...
- Indication
Levodopa on its own is formulated as an oral inhalation powder indicated for intermittent treatment of off episodes in Parkinson's patients who are already being treated with carbidopa and levodopa. Levodopa is most commonly formulated as an oral tablet with a peripheral dopa decarboxylase inhibitor indicated for treatment of Parkinson's disease, post-enceph...
- Associated Conditions
- Paralysis agitans, Parkinson's Disease (PD), Parkinsonism, Parkinsonism post encephalitic, Restless Legs Syndrome (RLS), Advanced Motor fluctuations
- Associated Therapies
- -
Behavioural Profiling of Disease-related Cognitive and Motor Impairment in PD
- Conditions
- Interventions
- First Posted Date
- 2024-02-23
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- University Hospital Bispebjerg and Frederiksberg
- Target Recruit Count
- 68
- Registration Number
- NCT06275633
- Locations
- 🇩🇰
University Hospital Bispebjerg and Frederiksberg, Copenhagen, Region Hovedstaden, Denmark
Cortical Electrophysiology of Response Inhibition in Parkinson's Disease
- First Posted Date
- 2024-01-31
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Emory University
- Target Recruit Count
- 80
- Registration Number
- NCT06234995
- Locations
- 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States
🇺🇸Emory Brain Health Center, Atlanta, Georgia, United States
The Correlation of Reduction of Levodopa and Non-motor Symptoms of Parkinson's Disease After Deep Brain Stimulation
- First Posted Date
- 2023-06-13
- Last Posted Date
- 2023-07-25
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 338
- Registration Number
- NCT05901350
- Locations
- 🇨🇳
Chao Zhang, Jinan, Sichuan, China
Improving Therapeutic Learning for PTSD
- First Posted Date
- 2020-09-22
- Last Posted Date
- 2023-08-30
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 120
- Registration Number
- NCT04558112
- Locations
- 🇺🇸
University of Wisconsin, Madison, Wisconsin, United States
🇺🇸University of Texas, Austin, Texas, United States
Dopaminergic Dysfunction in Late-Life Depression
- Conditions
- Interventions
- First Posted Date
- 2020-07-14
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 100
- Registration Number
- NCT04469959
- Locations
- 🇺🇸
Vanderbilt Psychiatric Hospital, Nashville, Tennessee, United States
🇺🇸University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Effects of 5HTP and LDOPA on CNS Excitability After SCI
- Conditions
- Interventions
- First Posted Date
- 2019-06-27
- Last Posted Date
- 2022-10-17
- Lead Sponsor
- Jessica M D'Amico
- Target Recruit Count
- 30
- Registration Number
- NCT04000919
- Locations
- 🇺🇸
University of Louisville, Kentucky Spinal Cord Injury Research Centre, Louisville, Kentucky, United States
Oxytocin and Dopamine's Effect on Vicarious Optimism
- Conditions
- Interventions
- First Posted Date
- 2019-03-26
- Last Posted Date
- 2019-03-26
- Lead Sponsor
- Beijing Normal University
- Target Recruit Count
- 156
- Registration Number
- NCT03891095
- Locations
- 🇨🇳
Beijing Normal University, Beijing, Beijing, China
L-DOPA vs. Placebo for Depression and Psychomotor Slowing in Older Adults
- Conditions
- Interventions
- First Posted Date
- 2018-12-03
- Last Posted Date
- 2023-05-22
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 51
- Registration Number
- NCT03761030
- Locations
- 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
Pharmacological Modulation of Belief Salience
- Conditions
- Interventions
- First Posted Date
- 2018-11-27
- Last Posted Date
- 2019-10-10
- Lead Sponsor
- King's College London
- Target Recruit Count
- 30
- Registration Number
- NCT03754062
- Locations
- 🇬🇧
Centre for Neuroimaging Sciences, London, United Kingdom
Clinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man Syndrome
- First Posted Date
- 2017-08-01
- Last Posted Date
- 2019-04-22
- Lead Sponsor
- Bennett Lavenstein
- Target Recruit Count
- 10
- Registration Number
- NCT03235037
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.